OncoMatch/Clinical Trials/NCT03596086
HSV-tk + Valacyclovir + SBRT + Chemotherapy for Recurrent GBM
Is NCT03596086 recruiting? Yes, currently enrolling (May 2026). This Phase 1/2 trial studies ADV/HSV-tk (gene therapy) for glioblastoma multiforme.
Treatment: ADV/HSV-tk (gene therapy) — Study to assess the safety and efficacy of HSV-tk (gene therapy), valacyclovir, radiotherapy and chemotherapy in recurrent glioblastoma multiforme.
Check if I qualifyExtracted eligibility criteria
Cancer type
Glioblastoma
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Must have received: surgery — for glioblastoma
has had prior surgery and radiotherapy /chemotherapy for the glioblastoma
Must have received: radiation therapy — for glioblastoma
has had prior surgery and radiotherapy /chemotherapy for the glioblastoma
Must have received: chemotherapy — for glioblastoma
has had prior surgery and radiotherapy /chemotherapy for the glioblastoma
Cannot have received: immunomodulatory therapy
Exception: allowed if >3 months prior
Prior treatment with immunomodulatory therapy, immunotherapy, and/or gene vector therapy in the past 3 months
Cannot have received: immunotherapy
Exception: allowed if >3 months prior
Prior treatment with immunomodulatory therapy, immunotherapy, and/or gene vector therapy in the past 3 months
Cannot have received: gene vector therapy
Exception: allowed if >3 months prior
Prior treatment with immunomodulatory therapy, immunotherapy, and/or gene vector therapy in the past 3 months
Cannot have received: cytotoxic chemotherapy
Exception: allowed if >3 weeks prior
Any cytotoxic chemotherapy, RT, or immunotherapy or any investigational drug for this brain tumor within 3 weeks of study treatment start
Cannot have received: radiation therapy
Exception: allowed if >3 weeks prior
Any cytotoxic chemotherapy, RT, or immunotherapy or any investigational drug for this brain tumor within 3 weeks of study treatment start
Cannot have received: immunotherapy
Exception: allowed if >3 weeks prior
Any cytotoxic chemotherapy, RT, or immunotherapy or any investigational drug for this brain tumor within 3 weeks of study treatment start
Cannot have received: investigational drug
Exception: allowed if >3 weeks prior
Any cytotoxic chemotherapy, RT, or immunotherapy or any investigational drug for this brain tumor within 3 weeks of study treatment start
Lab requirements
Blood counts
Platelet count > 100,000/ml, ANC > 1500/ml, Hgb > 10 gm/dL, Normal partial thromboplastin time (PTT) and Pro-Thrombin Time (PT)
Kidney function
serum creatinine < 1.5 mg/dL
Liver function
T. bilirubin < 2.5 mg/dL, ALT, AST, GGT and AP < 2 x normal
serum creatinine < 1.5 mg/dL; T. bilirubin < 2.5 mg/dL, ALT, AST, GGT and AP < 2 x normal; Platelet count > 100,000/ml , ANC> 1500/ml , Hgb> 10 gm/dL; Normal partial thromboplastin time (PTT) and Pro-Thrombin Time (PT)
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Houston Methodist Neurological Institute · Houston, Texas
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify